Swiss National Bank grew its holdings in Organon & Co. (NYSE:OGN – Get Rating) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 614,175 shares of the company’s stock after acquiring an additional 12,700 shares during the quarter. Swiss National Bank owned 0.24% of Organon & Co. worth $17,154,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Ellevest Inc. raised its position in Organon & Co. by 311.9% during the third quarter. Ellevest Inc. now owns 1,145 shares of the company’s stock valued at $27,000 after purchasing an additional 867 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Organon & Co. during the third quarter worth about $28,000. Massmutual Trust Co. FSB ADV raised its holdings in Organon & Co. by 132.2% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 1,066 shares of the company’s stock valued at $30,000 after buying an additional 607 shares during the last quarter. Romano Brothers AND Company acquired a new stake in Organon & Co. during the 4th quarter worth approximately $31,000. Finally, Glassman Wealth Services grew its holdings in Organon & Co. by 63.8% during the 4th quarter. Glassman Wealth Services now owns 1,155 shares of the company’s stock worth $32,000 after acquiring an additional 450 shares during the last quarter. Institutional investors and hedge funds own 75.74% of the company’s stock.
Analyst Ratings Changes
Separately, Raymond James began coverage on shares of Organon & Co. in a research note on Wednesday, March 15th. They issued an “outperform” rating and a $33.00 price objective on the stock.
Organon & Co. Stock Performance
Organon & Co. (NYSE:OGN – Get Rating) last released its earnings results on Thursday, May 4th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.10). The business had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.54 billion. Organon & Co. had a negative return on equity of 119.00% and a net margin of 12.14%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.65 EPS. As a group, research analysts predict that Organon & Co. will post 4.22 EPS for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Monday, May 15th will be issued a dividend of $0.28 per share. The ex-dividend date is Friday, May 12th. This represents a $1.12 annualized dividend and a dividend yield of 5.37%. Organon & Co.’s dividend payout ratio is currently 38.36%.
Organon & Co. Profile
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Featured Stories
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Get Rating).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
